Literature DB >> 25936483

The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Stella S Daskalopoulou1, Doreen M Rabi2, Kelly B Zarnke3, Kaberi Dasgupta4, Kara Nerenberg5, Lyne Cloutier6, Mark Gelfer7, Maxime Lamarre-Cliche8, Alain Milot9, Peter Bolli10, Donald W McKay11, Guy Tremblay12, Donna McLean13, Sheldon W Tobe14, Marcel Ruzicka15, Kevin D Burns15, Michel Vallée16, G V Ramesh Prasad14, Marcel Lebel17, Ross D Feldman18, Peter Selby19, Andrew Pipe20, Ernesto L Schiffrin21, Philip A McFarlane22, Paul Oh23, Robert A Hegele24, Milan Khara25, Thomas W Wilson26, S Brian Penner27, Ellen Burgess28, Robert J Herman29, Simon L Bacon30, Simon W Rabkin31, Richard E Gilbert32, Tavis S Campbell33, Steven Grover34, George Honos35, Patrice Lindsay36, Michael D Hill37, Shelagh B Coutts38, Gord Gubitz39, Norman R C Campbell40, Gordon W Moe41, Jonathan G Howlett42, Jean-Martin Boulanger43, Ally Prebtani44, Pierre Larochelle45, Lawrence A Leiter46, Charlotte Jones47, Richard I Ogilvie48, Vincent Woo49, Janusz Kaczorowski50, Luc Trudeau51, Robert J Petrella52, Swapnil Hiremath53, James A Stone54, Denis Drouin55, Kim L Lavoie56, Pavel Hamet57, George Fodor21, Jean C Grégoire58, Anne Fournier59, Richard Lewanczuk13, George K Dresser60, Mukul Sharma61, Debra Reid62, Geneviève Benoit63, Janusz Feber64, Kevin C Harris65, Luc Poirier66, Raj S Padwal67.   

Abstract

The Canadian Hypertension Education Program reviews the hypertension literature annually and provides detailed recommendations regarding hypertension diagnosis, assessment, prevention, and treatment. This report provides the updated evidence-based recommendations for 2015. This year, 4 new recommendations were added and 2 existing recommendations were modified. A revised algorithm for the diagnosis of hypertension is presented. Two major changes are proposed: (1) measurement using validated electronic (oscillometric) upper arm devices is preferred over auscultation for accurate office blood pressure measurement; (2) if the visit 1 mean blood pressure is increased but < 180/110 mm Hg, out-of-office blood pressure measurements using ambulatory blood pressure monitoring (preferably) or home blood pressure monitoring should be performed before visit 2 to rule out white coat hypertension, for which pharmacologic treatment is not recommended. A standardized ambulatory blood pressure monitoring protocol and an update on automated office blood pressure are also presented. Several other recommendations on accurate measurement of blood pressure and criteria for diagnosis of hypertension have been reorganized. Two other new recommendations refer to smoking cessation: (1) tobacco use status should be updated regularly and advice to quit smoking should be provided; and (2) advice in combination with pharmacotherapy for smoking cessation should be offered to all smokers. The following recommendations were modified: (1) renal artery stenosis should be primarily managed medically; and (2) renal artery angioplasty and stenting could be considered for patients with renal artery stenosis and complicated, uncontrolled hypertension. The rationale for these recommendation changes is discussed.
Copyright © 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25936483     DOI: 10.1016/j.cjca.2015.02.016

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  99 in total

Review 1.  The 2015 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: An update.

Authors:  Sherilyn K D Houle; Raj Padwal; Luc Poirier; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2015-07

Review 2.  First-line combination therapy versus first-line monotherapy for primary hypertension.

Authors:  Javier Garjón; Luis Carlos Saiz; Ana Azparren; José J Elizondo; Idoia Gaminde; Mª José Ariz; Juan Erviti
Journal:  Cochrane Database Syst Rev       Date:  2017-01-13

3.  Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention and treatment of hypertension in adults for pharmacists: An update.

Authors:  Sarah A Lamb; Yazid N Al Hamarneh; Sherilyn K D Houle; Alexander A Leung; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2017-11-29

4.  Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.

Authors:  Kelly R McMahon; Maya Harel-Sterling; Michael Pizzi; Louis Huynh; Erin Hessey; Michael Zappitelli
Journal:  Pediatr Nephrol       Date:  2018-09-14       Impact factor: 3.714

Review 5.  Unique approaches to hypertension control in China.

Authors:  Ji-Guang Wang
Journal:  Ann Transl Med       Date:  2018-08

Review 6.  Current and Future Treatment of Hypertension in the SPRINT Era.

Authors:  Robert A Phillips
Journal:  Methodist Debakey Cardiovasc J       Date:  2015 Oct-Dec

7.  Barriers to conducting ambulatory and home blood pressure monitoring during hypertension screening in the United States.

Authors:  Ian M Kronish; Shia Kent; Nathalie Moise; Daichi Shimbo; Monika M Safford; Robert E Kynerd; Ronan O'Beirne; Alexandra Sullivan; Paul Muntner
Journal:  J Am Soc Hypertens       Date:  2017-07-06

8.  Hypertension Canada's 2016 Canadian Hypertension Education Program guidelines for pharmacists: An update.

Authors:  Yazid N Al Hamarneh; Sherilyn K D Houle; Raj Padwal; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2016-10-06

9.  Trends in the diagnosis and management of hypertension: repeated primary care survey in South West England.

Authors:  Natasha Mejzner; Christopher E Clark; Lindsay Fp Smith; John L Campbell
Journal:  Br J Gen Pract       Date:  2017-03-27       Impact factor: 5.386

10.  Circulating miR-92a expression level in patients with essential hypertension: a potential marker of atherosclerosis.

Authors:  Y Huang; S Tang; C Ji-Yan; C Huang; J Li; A-P Cai; Y-Q Feng
Journal:  J Hum Hypertens       Date:  2016-09-15       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.